Early-Stage Biotech Valuation Models
Valuing early-stage biotech companies presents a distinct challenge within the U.S. life sciences ecosystem, where limited revenue visibility intersects with high scientific uncertainty. Unlike traditional sectors, these companies are often pre-commercial, relying on pipeline potential, intellectual property, and regulatory milestones to justify investment. As a result, valuation models must integrate scientific risk, clinical timelines, and … Read more